Exploring the intricate connection between genetics and cardiovascular health, cardiovascular pharmacogenomics stands at the forefront of medical innovation. This field delves into the genetic factors influencing how individuals respond to cardiovascular drugs, with a primary objective of fine-tuning treatment outcomes and mitigating potential adverse effects. Through a comprehensive analysis of genetic variations impacting drug metabolism, efficacy, and toxicity, cardiovascular pharmacogenomics endeavors to customize medication regimens based on each patient's distinct genetic profile. This personalized approach not only holds the potential to optimize the effectiveness of cardiovascular therapies but also aims to minimize the occurrence of side effects, thereby elevating overall patient outcomes. In an era of advancing genomic understanding, cardiovascular pharmacogenomics emerges as a pivotal player in the ongoing evolution toward precision medicine, paving the way for more nuanced and targeted treatments in the realm of cardiovascular diseases.
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, Tianjin University, China
Title : Not So Idiopathic After All: Genotype, Phenotype and IL-1 Blockade Response Converge in Recurrent Pericarditis
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Beyond the Heart in Cardiovascular Magnetic Resonance Imaging: Prevalence and Clinical Significance of Incidental Extracardiac Findings
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Cardiovascular mortality in colon cancer a patient characteristics analysis: Population-based study
Nouf, KAU, Saudi Arabia
Title : Improving Screening and Treatment of Iron Deficiency in Patients with Heart Failure with Reduced Ejection Fraction: A Two-Cycle Quality Improvement Project
Danish Malik, University Hospitals Dorset NHS Foundation Trust, United Kingdom